Eflapegrastim, is a long-acting G-CSF analog, a leukocyte growth factor.
Trade name Rolvedon
Routes of administration Subcutaneous
It is used to reduce the risk of febrile neutropenia in people with non-myeloid malignancies receiving myelosuppressive anti-cancer agents.
The most common side effects are fatigue, nausea, diarrhea, bone pain, headache, fever, anemia, rash, myalgia, arthralgia, and back pain.[4]
Eflapegrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
Its efficacy has been shown to be non-inferior to pegfilgrastim.